Black Diamond Therapeutics, Inc.

Clinical Update on BDTX-1535 Potential First and Best-in-Class 4th Generation EGFR Inhibitor



June 27, 2023

Forward-Looking Statements

This presentation contains forward-looking statements of Black Diamond Therapeutics, Inc. ("we," "us," "our") within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements include all statements that are not historical facts, and in some cases, can be identified by terms such as "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "potential," "continue," "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements contained in this presentation include, but are not limited to, statements regarding our future financial or business performance, conditions, plans, prospects, trends or strategies and other financial and business matters; our current and prospective product candidates, the timing and advancement of current and planned clinical trials, our ability to replicate results achieved in our preclinical studies or clinical trials; research and development costs; the competitive landscape and market for our product candidates; our ability to maintain our intellectual property portfolio; and the timing and success of our development and commercialization of our product candidates, including our ability to establish and maintain collaborations or strategic relationships. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), as well as discussions of potential risks, uncertainties, and other important factors in our other subsequent filings with the SEC. In addition, we have not conducted any head-to-head studies comparing our product candidates to any third-party drug products or candidates, whether investigated or approved. Information regarding other drug products in this presentation is meant to provide context for illustrative purposes only. Because there are no head-to-head studies, no conclusions should be made based on cross-study comparisons. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact.





Mutant EGFR NSCLC Landscape and BDTX-1535 Profile

CEO Introduction to BDTX-1535 Clinical Update

Liz Buck, Ph.D. Chief Scientific Officer

Sergey Yurasov, M.D., Ph.D. **Chief Medical Officer**



Melissa Johnson, M.D. Director of Lung Cancer Research Sarah Cannon



Chief Business and Financial Officer

Agenda

BDTX-1535 Phase 1 NSCLC Clinical Data


KOL Perspective: Post-Osimertinib NSCLC

Key Milestones





BDTX-1535 Clinical Proof-of-Concept Achieved in Phase 1 Dose Escalation



HERAPEUTICS

BDTX-1535 Phase 1 Highlights:

Clinical Proof-of-Activity in NSCLC

Dose linear PK confirms 24 hr target coverage

BDTX-1535 MasterKey

Mutation Coverage

Clinical evidence

of CNS Anti-tumor

Activity

ctDNA reduction confirms loss of mutant alleles in NSCLC

5

6

Clinical activity

across mutation

families

Radiographic responses in EGFR mutant NSCLC

3

Manageable EGFR


TKI Safety Profile

BLACK DIAMOND THERAPEUTICS

Black Diamond's MasterKey Approach Targets Oncogene Mutation Families

Classical/Current Approach:

Targeting single mutations in individual tumor types




Limited addressable patient population



Genetic profiling of cancer patients via Next Generation Sequencing (NGS)

> Less than 15% patients¹ with metastatic cancer eligible for approved precision oncology medicines

Black Diamond MasterKey: Targeting family of oncogenic mutations




Expanded addressable patient population








BDTX-1535: Selective EGFR MasterKey Inhibitor with Clinical Proof-of-Concept



Evolving EGFR Mutated NSCLC Market Predicted to Grow to Over \$6B Per Year¹ Globally




5. Costa DB, Transl Lung Cancer Res. 2016

BDTX-1535 Demonstrated Potent Inhibition of EGFR Intrinsic Driver Mutations, C797S Resistance Mutation, and EGFR Amplification



BDTX-1535 potently targets >50 EGFR MasterKey mutations






1. BDTX-1535 has demonstrated activity against greater than 50 intrinsic driver resistance mutations


Source: AACR 2023 Poster

BDTX-1535: Designed as an Irreversible Brain Penetrant EGFR MasterKey Inhibitor

BDTX-1535 Exhibited Durable Irreversible Target Inhibition In Preclinical C797S mutant Study



BDTX-1535 Exhibited Superior Brain Exposure Kpuu (rat)





Kpuu Partition Coefficient Calculation: AUCbrain: blood x plasma Fu/brain Fu

C797S BaF3 xenograft model




BDTX-1535 – Potentially First and Best-in-Class 4th Gen EGFR TKI

Critical Features	BDTX-1535	BLU-945 ^{1,2}	BLU-701 ^{3,4} /525 ⁵	THE-349 ⁶	STX-241 ⁷
Classical Driver MasterKey Mutations	\bigcirc	\bigcirc	\bigcirc	\bigcirc	\bigcirc
C797S Acquired MasterKey Resistance	\bigcirc	\bigcirc	\bigcirc	\bigotimes	\bigcirc
Intrinsic Driver MasterKey Mutations	\bigcirc	?	?	?	?
Covalent Binding for potency/durability	\bigcirc	\mathbf{O}	\mathbf{O}	\mathbf{O}	?
CNS Penetration	\bigcirc	?	\bigcirc	\bigcirc	\bigcirc
Status	Phase 1 Monotherapy	Combination Study	Deprioritized / preclinical	Preclinical	Preclinical

BLACK DIAMOND THERAPEUTICS Note: Intrinsic drivers also called "Atypical", "PACC", and "Uncommon" mutations

1.) Eno, J Med Chem 2022; 2.) Elamin, ASCO 2023 Annual Meeting; 3.) Spira, ASCO 2022; 4.) Blueprint Medicines Investor Day, SEC 2022; 5.) Blueprint Medicines Corporate Presentation, June 2023; 6.) Zhang, EORTC-NCI-AACR 2022; 7.) Scorpion Therapeutics Press Release, April 2023




Note: Intrinsic drivers also called "Atypical", "PACC" and "Uncommon" mutations

THERAPEUTICS

1. John, Cancer Epidemiology, 2022; 2. Kuiper, BJC 2016; 3. Piotrowska Z, ESMO 2022, LBA53 ELIOS; 4. Ramalingam, WCLC 2022; 5. Keynote-789 ASCO 2023

Current Treatment Paradigm for EGFR mutant NSCLC BDTX-1535 Opportunity in Future 2L and 1L EGFR+ NSCLC Treatment Landscape





Modified from KANTAR Health 2020

THERAPEUTICS

BDTX-1535 Phase 1 Dose Escalation Delivered Clinical Proof-of-Activity in NSCLC

Dose linear PK confirms 24 hr target coverage 6 **Clinical activity** Manageable EGFR across mutation **TKI Safety Profile** families **BDTX-1535** MasterKey **Mutation Coverage** 3 5 Radiographic ctDNA reduction responses in EGFR confirms loss of mutant NSCLC mutant alleles in NSCLC **Clinical evidence** of CNS Anti-tumor Activity

BLACK DIAMOND THERAPEUTICS

BDTX-1535 Phase 1 Dose Escalation for NSCLC & GBM with Targeted EGFR Mutations

Mutation Matched Phase 1 Study



NSCLC Acquired & Intrinsic Cohorts:


- EGFR mutations at the time of progression:
 - Intrinsic driver, OR
 - Acquired resistance
- Progression on 1L 3rd Gen EGFR TKI
- Exclusion of EGFR T790M, Ex20ins, KRAS mutations, cMET amplification



Recurrent GBM Cohort:


- EGFR alterations at the time of resection
- Wild-type isocitrate dehydrogenase (IDH)
- Recurrent disease

Dose Escalation Patients: measurable and non-measurable disease Primary objective: safety and PK




• No DLTs at ≤200 mg QD





BDTX-1535-101 Phase 1 Dose Escalation Patient Characteristics




NSCLC				
Patient Characteristics and Treatment History	All Treated (N=24)			
Age, median (range)	65 (47, 81)			
Female	16 (67%)			
ECOG PS				
0	7 (29%)			
1	16 (71%)			
Non-smoker	17 (71%)			
Prior lines of therapies				
median (min, max)	2 (1, 9)			
Prior anti-cancer agents				
EGFR TKI	24 (100%)			
Chemo	16 (67%)			
Anti-angiogenic or CPIs	10 (42%)			
EGFR TKIs received				
Osimertinib	19 (79%)			
1 st line treatment	16 (67%)			
Erlotinib	4 (17%)			
Afatinib	3 (13%)			
Gefitinib	2 (8%)			
Dacomitinib	1 (4%)			
BLU-701	1 (4%)			

GBM				
Patient Characteristics and	All Treated			
Treatment History	(N=27)			
Age, median (range)	58 (41, 85)			
Female	10 (37%)			
Karnofsky PS				
90	4 (17%)			
80	12 (50%)			
70	5 (21%)			
60	3 (13%)			
Prior lines of therapies				
median (min, max)	2 (1, 4)			
Prior anti-cancer agents				
TMZ	27 (100%)			
Anti-angiogenic or CPIs	11 (41%)			
Chemo	7 (26%)			

BLACK DIAMOND THERAPEUTICS BDTX-1535 Linear Plasma PK Profile Supports Daily Dosing To Achieve 24 Hour Target Coverage in NSCLC and GBM Cohorts



Mean plasma concentration-time profile of BDTX-1535



- Clinical activity observed in 100-300 mg QD cohorts
- Exposure was dose proportional with half-life ~15 hours to support daily dosing


BLACK

300 mg QD N=11 N=9

400 mg QD N=12 N=9

Dose Escalation Treatment Emergent Adverse Events Related to BDTX-1535





- TEAEs events occurring ≥6%
- Majority of adverse events were mild or moderate
- Rash, diarrhea, stomatitis and paronychia were consistent with WT EGFR effect
- No unexpected safety signal was identified


BLACK DIAMOND THERAPEUTICS

TEAEs: Treatment Emergent Adverse Events

20May2023 BDTX-1535-101 clinical data extract

Comparison of BDTX-1535 Related Adverse Events in NSCLC Patients BDTX-1535 200 mg QD was Observed to be a Well Tolerated Dose







TEAEs = Treatment Emergent Adverse Events; DLT = dose limiting toxicity

20May2023 BDTX-1535-101 clinical data extract;


BDTX-1535 Summary of NSCLC Data



BDTX-1535 Dose Escalation NSCLC Patients Reflect Real World EGFR Mutation Landscape Post Osimertinib



n=24 patients enrolled in dose escalation; n=12 patients efficacy evaluable





Patient NGS Reports (redacted) 20May2023 BDTX-1535-101 clinical data extract NSCLC Efficacy Evaluable Patient Population From BDTX-1535 Phase 1 Dose Escalation




Assigned Dose (QD) (n =24)	Reasons for Exclusion From Efficacy Evaluable Group	Efficacy Evaluable Group (n = 12)	
25 mg (n =1) 50 mg (n = 2)	Sub-therapeutic doses (n=3)	25 mg (n = 0) 50 mg (n = 0)	
100 mg (n = 2)	Physician decision to withdraw patient (n = 1)*	100 mg (n = 1)	
200 mg (n = 6)	None	200 mg (n = 6)	
300 mg (n = 6)	Protocol eligibility deviation (n = 2) Nine lines of therapy (n =1) Post-baseline tumor assessment is pending (n=1)	300 mg (n = 2)	
400 mg (n = 7)	Non-measurable disease (n =1) Treatment discontinuation due to AE (n = 1)* Consent withdrawal by subject (n = 2)*	400 mg (n = 3)	



RECIST1.1 Radiographical Responses in Efficacy Evaluable NSCLC Patients Treated with Therapeutic Doses of BDTX-1535





- Patients with measurable disease who have received 3rd gen EGFR TKI, no 1st or 2nd generation EGFR TKI
- Population to be Assessed for ORR in Expansion Cohorts • No more than 2 prior lines of therapy

BLACK

DIAMOND

THERAPEUTICS


• Patients with no prior osimertinib excluded

*patients with no prior osimertinib; **patients were accepted with 1st line chemo followed by osimertinib

20May 2023 BDTX-1535-101 clinical data extract; additional updates as of 16Jun2023




BDTX-1535: Emerging Evidence of Durable Tumor Response in NSCLC





Patients with measurable disease who have received 1st line osimertinib, no 1st or 2nd generation EGFR TKI and underwent at least 1 post baseline scan 20May 2023 BDTX-1535-101 clinical data extract; additional updates as of 16Jun2023



BLACK DIAMOND THERAPEUTICS

BDTX-1535-101 Data Extract 20May2023; ctDNA data 07Jun2023


SoD - Sum of diameters per RECIST 1.1; VAF - variant allelic fraction

Confirmed PR by RECIST1.1 in NSCLC Patient with EGFR L858R + L718Q + C797S Complex Mutation

Classical Driver L858R Intrinsic Driver

C797S

Baseline: SEP 2022




February 21, 2023





Confirmed PR by RECIST1.1 in NSCLC Patient with **EGFR L747P Intrinsic Driver Mutation**



Intrinsic Driver

Confirmed PR by RECIST1.1 in NSCLC Patient with EGFR L747P Intrinsic Driver Mutation


Baseline: Oct 2022



May, 2023








DIAMOND BDTX-1535-1
THERAPEUTICS SoD - Sum of

BDTX-1535-101 Data Extract 20May2023; ctDNA data 07Jun2023

SoD - Sum of diameters per RECIST 1.1; VAF - variant allelic fraction

Confirmed PR by RECIST1.1 in NSCLC Patient With EGFR Exon 19del + C797S Acquired Resistance Mutation

C797S



BLACK DIAMOND THERAPEUTICS


BDTX-1535-101 Data Extract 20May2023 and additional update on 16Jun2023;

SoD - Sum of diameters per RECIST 1.1; VAF - variant allelic fraction

Confirmed PR by RECIST1.1 in NSCLC Patient With EGFR Exon 19del + C797S Acquired Resistance Mutation

Baseline: Feb 20, 2023






Off oxygen and able to travel to France

On oxygen



APR 10, 2023

Clinical Benefit in NSCLC Patient With Non-Measurable Disease EGFR G719A + L861Q Complex Mutation



* L861Q mutant allele was not detected in baseline and post-dose ctDNA plasma samples BDTX-1535-101 Data Extract 20May2023; ctDNA data 07Jun2023; VAF – variant allelic fraction

DIAMOND

THERAPEUTICS


Intrinsic Driver

Intrinsic Driver

BDTX-1535 200 mg QD Dose to be Evaluated for ORR in Expansion Cohorts To Support Path To Approval in NSCLC


Dose Escalation

Patients: measurable and non-measurable disease Primary objective: safety and PK



Expansion Cohorts

NSCLC Patients: measurable disease only, ≤2 prior therapies Primary objective: ORR by RECIST1.1




2L NSCLC with EGFR intrinsic driver mutations +/- CNS metastasis

1L NSCLC with EGFR intrinsic driver mutations +/- CNS metastasis (after discussion with the FDA)

- The protocol allows for evaluation of additional doses in expansion cohorts
- Recommended phase 2 dose will be selected after data review with the FDA (FDA Project Optimus)
- Selection of doses(s) for expansion cohorts is based on optimal exposure response analysis of safety, ctDNA and target lesion reduction
- Primary endpoint of ORR by RECIST1.1 is an acceptable (FDA) efficacy surrogate endpoint in NSCLC

Competitor Data in Patients with Prior 3rd Generation EGFR TKI



Note: These data are derived from different clinical trials with differences in trial design and patient populations. As a result, cross-trial comparisons cannot be made, and no head-to-head clinical trials have been conducted.

*2 confirmed responses out of 42 patients from interim DE data presented

BLACK

DIAMOND

THERAPEUTICS

1. Bauml, ASCO 2021; 2. JNJ Press Release, 2021; 3. Janne, ASCO Cancer Discovery 2022; 4. Keynote-789, ASCO2023; 5. Elamin et. al., ASCO 2023



- Initiate BDTX-1535 dose expansion in 2L NSCLC with ORR as primary endpoint, 2H 2023
 - Initiation of dose expansion cohort in newly diagnosed patients with intrinsic driver mutations

 NSCLC
 Alignment with FDA on dosing strategy for pivotal study (EOP1 meeting), Q4 2023

- Present BDTX-1535 dose escalation data in NSCLC at a medical conference, Q4 2023
- Update on clinical dose expansion cohorts, 2024
- Clinical update on BDTX-1535 Phase 1 dose escalation in RR GBM, Q4 2023

СМС

GBM

• Complete capsule to tablet transition (potential commercial formulation), Q3 2023

Key Anticipated BDTX-1535 Milestones



Partnership:	partnership@bdtx.com
Investors:	investors@bdtx.com
Media:	<u>media@bdtx.com</u>

